Lung Cancer News

CHICAGO — Most individuals with cancer who used an AI-based nutritional platform reported the application helped them regulate their diets and improved their quality of life, according to study results presented at ASCO Annual Meeting.

Compared with non-Hispanic white individuals, patients from racial and ethnic minority groups experienced similar clinical benefits when participating in phase 1 trials for advanced cancers, data published in JAMA Network Open showed.

About 40% of cancer cases and nearly half of cancer deaths among U.S. adults aged 30 years or older can be attributable to modifiable risk factors, according to a study led by American Cancer Society researchers.

Tiragolumab plus atezolizumab added to chemotherapy did not extend survival outcomes as first-line therapy of locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, interim results from a randomized study showed.

SAN DIEGO — Smokers who used electronic cigarettes after quitting had more risk for lung cancer than those who quit but did not use e-cigarettes, according to a study presented at the American Thoracic Society International Conference.

Individuals with laryngeal cancer who stop smoking in the 2- to 4-week window between diagnosis and their first treatment can significantly improve their response to therapy, survival rates and quality of life.

The likelihood for lung cancer screening uptake was reduced among current vs. never e-cigarette users, according to results published in JAMA Network Open.

Christian Rolfo, MD, PhD, MBA, will be the director of the division of medical oncology at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, as of Aug. 15.

CHICAGO — Individuals with advanced cancer who received a two-component medical cannabis oil reported improvement in cancer-related pain, results from a randomized study showed.

Adjuvant durvalumab failed to improve outcomes compared with placebo for certain patients with early-stage lung cancer, according to the agent’s manufacturer.